MetaCap

SAB Biotherapeutics Insider Trades

NASDAQ: SABSHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

2.98+0.09 (+3.11%)

At close: Oct 9, 4:00 PM ET · Delayed 15 min

Last 12 months

Purchases
0 · $0
Sales
0 · $0
Shares bought / sold
0 / 0
Net activity
Net buying $0

SAB Biotherapeutics insider activity

Over the last 12 months, SAB Biotherapeutics insiders reported 4 transactions on SEC Form 4: 0 open-market purchases and 0 sales. The most recent filing shows Kropotova Alexandra (CHIEF MEDICAL OFFICER) reporting a transaction in 473 shares on Sep 17, 2026. Insider sales are common for compensation, tax and diversification reasons, while open-market purchases are rarer; tracking both helps put SABS's ownership changes in context.

Summary generated from market data by MetaCap's automated system. Methodology

SABS insider transactions

SAB Biotherapeutics insider transactions
DateInsiderTypeSharesValueFiling
Sep 17, 2026Kropotova AlexandraCHIEF MEDICAL OFFICERTax withholding473—Form 4
Jun 25, 2026Kropotova AlexandraCHIEF MEDICAL OFFICERTax withholding988—Form 4
Mar 24, 2026Kropotova AlexandraCHIEF MEDICAL OFFICERTax withholding988—Form 4
Dec 11, 2025Kropotova AlexandraCHIEF MEDICAL OFFICERTax withholding988—Form 4
Sep 29, 2025Sessa Capital (Master), L.P. & Sessa Capital GP, LLC & Sessa Capital IM, L.P. & Sessa Capital IM GP, LLC & Petry JohnDirectorOption exercise1,740,000$3.04MForm 4
Sep 29, 2025Moin AndrewDirectorOption exercise1,740,000$3.04MForm 4
Sep 19, 2025Kropotova AlexandraCHIEF MEDICAL OFFICERTax withholding1,977—Form 4
Mar 27, 2025Kropotova AlexandraCHIEF MEDICAL OFFICERTax withholding1,179—Form 4
Dec 18, 2024Kropotova AlexandraCHIEF MEDICAL OFFICERTax withholding9,072—Form 4

Transaction codes follow SEC Form 4: P = open-market purchase, S = open-market sale, A = grant or award, M = option exercise, F = shares withheld for taxes. About Form 4

Related